438 476
[10]
Abdollah F, Briganti A, Montorsi F, et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 2015;67:839–49.
[11]
Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: Results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2015;67:299–309.
[12]
Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015;67: 852–63.[13]
Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatec- tomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomog- raphy. Eur Urol 2011;60:935–43.[14]
Tilki D, Mandel P, Seeliger F, et al. Salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy. J Urol 2015;193:484–90.
[15]
Karnes RJ, Murphy CR, Bergstralh EJ, et al. Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomog- raphy. J Urol 2015;193:111–6.[16]
Jilg CA, Rischke HC, Reske SN, et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012;188:2190–7.
[17]
Osmonov DK, Aksenov AV, Boller A, et al. Extended salvage pelvic lymph node dissection in patients with recurrent prostate cancer. Adv Urol 2014;2014:321619.
[18] EAU Guidelines on Prostate Cancer. 2016.
https://uroweb.org.
[19]
Sagalovich D, Calaway A, Srivastava A, Sooriakumaran P, Tewari AK. Assessment of required nodal yield in a high risk cohort undergoing extended pelvic lymphadenectomy in robotic-assisted radical pros- tatectomy and its impact on functional outcomes. BJU Int 2013; 111:85–94.
[20]
Satava RM. Identification and reduction of surgical error using simulation. Minim Invasive Ther Allied Technol 2005;14:257–61.
[21]
Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystec- tomy. Surgery 1992;111:518–26.[22]
Evangelista L, Briganti A, Fanti S, et al. New clinical indications for F/C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: A systematic review of the literature. Eur Urol 2016;70:161–75.
[23]
Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197–209.
[24]
Passoni NM, Suardi N, Abdollah F, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol 2014;32:38, e9-e16.[25]
Eden CG, Zacharakis E, Bott S. The learning curve for laparoscopic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer: implications for compliance with existing guide- lines. BJU Int 2013;112:346–54.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 3 2 – 4 3 8
438